{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-005280","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.407724+00:00","generated_at":"2026-06-03T18:08:49.004660+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bio-Path completes second dose cohort in Phase 1/1b trial of BP1002 in AML","bullets":["Second dose cohort (40 mg/m²) completed in dose escalation for refractory/relapsed AML patients, including venetoclax-resistant.","Trial will pause for FDA data review; next planned dose is 60 mg/m² in monotherapy.","BP1002 targets Bcl-2 at mRNA level, may overcome venetoclax resistance; preclinical data showed potent inhibition.","Phase 1b combination with decitabine expected after monotherapy cohorts; enrollment rates described as good."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-005280","json":"https://secwatch.observer/filing/0001558370-24-005280.json","markdown":"https://secwatch.observer/filing/0001558370-24-005280.md","text":"https://secwatch.observer/filing/0001558370-24-005280.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024005280/0001558370-24-005280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024005280/bpth-20240418x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T18:08:49.004660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}